Integrin antagonist 27
Integrin antagonist 27 (Compound 27) is a small molecule integrin αvβ3 antagonist with an affinity of 18 nM. Integrin antagonist 27 can be combined with Paclitaxel to selectively target αvβ3-positive metastatic cancer cells. Integrin antagonist 27 is used as an anticancer agent[1].
Product Specifications
CAS Number
593274-97-6
UNSPSC
12352005
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Integrin-Antagonists-27.html
Purity
98.0
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(O)C1=CC=CC(N2C(/C=C(C(N3CC(NC4=CC=C(C)C=C4)=O)=O)\NC3=O)=CC=C2)=C1
Molecular Formula
C24H20N4O5
Molecular Weight
444.44
References & Citations
[1]Dayam R, et al. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. J Med Chem. 2006 Jul 27;49 (15) :4526-4534.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB1684-500 1x 500 µL
P63 (Squamous, Basal & Myoepithelial Cell Marker), 0.2mg/mL
Sign In for Pricing
View Details 
TRC-B440505-50MG 50 mg
6-ethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid
Sign In for Pricing
View Details 
BNC040782-500 1x 500 µL
Bcl-2 (BCL2/782), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 